STOCK TITAN

Niki BioSolutions delays Q3 2026 financial report

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
NT 10-Q

Rhea-AI Filing Summary

Niki BioSolutions, Inc. expects to file its Form 10-Q for the quarter ended September 30, 2026, on or before the fifth calendar day following the prescribed due date. It attributes the delay to purchase price allocation accounting, asset valuations and consolidation of legacy-entity records after the July 20, 2026 corporate domestication and business combination with DiamiR Biosciences Corp. The company anticipates a significant change in results compared with the corresponding three- and nine-month periods of 2025.

Filing Explained

The company says it cannot yet reasonably estimate changes in revenue, operating expenses or net loss; it expects the Form 10-Q, which will provide full results, by the fifth calendar day after its prescribed due date.

Expected filing deadline 5 calendar days On or before the fifth calendar day following the prescribed due date for the quarterly report.
Quarter end September 30, 2026 Period covered by the delayed Form 10-Q.
Business combination date July 20, 2026 Date of the corporate domestication and business combination with DiamiR Biosciences Corp.
purchase price allocation accounting financial
"finalizing complex purchase price allocation accounting"
corporate domestication regulatory
"corporate domestication and business combination"
Corporate domestication is the legal process by which a company changes the jurisdiction where it is officially registered without necessarily moving its day-to-day operations, similar to a person changing their legal residence while keeping the same home and job. It matters to investors because the new legal home can change tax obligations, regulatory oversight, shareholder rights and takeover rules, which can affect a company’s costs, risks and stock value.
consolidation of historical financial records technical
"consolidation of historical financial records across legacy entities"
independent registered public accounting firm financial
"review by the Registrant’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does NIKI expect to file its delayed Q3 2026 Form 10-Q?

Niki BioSolutions expects to file the report on or before the fifth calendar day following the prescribed due date.

Why is NIKI’s Q3 2026 Form 10-Q delayed?

Niki BioSolutions is finalizing purchase price allocation accounting, asset valuations and consolidation of historical records across legacy entities following its July 20, 2026 corporate domestication and business combination with DiamiR Biosciences Corp. The evaluations also require review by the company’s independent registered public accounting firm.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

 

  

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 

 

FORM 12b-25

 

NOTIFICATION OF LATE FILING

OMB APPROVAL
OMB Number: 3235-0058
Expires: September 30, 2028
Estimated average burden
  hours per response ....……..2.50
 
SEC FILE NUMBER
 
CUSIP NUMBER
 

 

(Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

 

For Period Ended: September 30, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

 

For the Transition Period Ended: _______________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

 

PART I — REGISTRANT INFORMATION

 

Niki BioSolutions, Inc.

Full Name of Registrant

 

Aptorum Group Limited

Former Name if Applicable

 

116 Village Boulevard, Suite 200

Address of Principal Executive Office (Street and Number)

 

Princeton, NJ 08540

City, State and Zip Code

 

 

 

 

PART II — RULES 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

 

  (a)   The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
   
☒ (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
   
  (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

 

Niki BioSolutions, Inc. (the “Company”) is currently in the process of finalizing complex purchase price allocation accounting, asset valuations, and the consolidation of historical financial records across legacy entities following the corporate domestication and business combination with DiamiR Biosciences Corp. on July 20, 2026 (the “Transaction”) and therefore there is a delay in the filing of its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2026 (the “Form 10-Q”). Due to the ongoing nature of these accounting evaluations and the required review by the Registrant’s independent registered public accounting firm, a reasonable quantitative estimate of the changes in revenue, operating expenses, and net loss cannot be made at this time without unreasonable effort or expense. The Company expects to provide full financial results in the Form 10-Q, which will be filed on or before the fifth calendar day following the prescribed due date.

 

PART IV — OTHER INFORMATION

 

(1)Name and telephone number of person to contact in regard to this notification

 

Thomas Freeburg   908   366-9509
(Name)   (Area Code)   (Telephone Number)

 

(2)Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes ☐ No

 

(3)Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No

  

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

The Registrant anticipates that there will be a significant change in its results of operations for the three and nine months ended September 30, 2026, as compared to the corresponding periods of the prior fiscal year ended September 30, 2025.

 

These anticipated changes are primarily attributable to the completion of the Transaction. As a result of the Transaction, the Registrant’s financial statements for the third quarter of 2026 will reflect the consolidated operations, expanded research and development pipelines, and administrative expenses of the combined entity, as well as significant non-recurring transaction, legal, and accounting costs associated with closing and integrating the business combination.

 

2

 

 

Niki BioSolutions, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date November 17, 2026 By  Thomas Freeburg, CFO

 

3

Keep reading